Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guilford Seeks To Triple Gliadel Market With First-Line Indication

Executive Summary

Approval of Guilford Pharmaceuticals' Gliadel Wafer for first-line treatment of metastatic brain cancer could triple use of the product, the company reported.

You may also be interested in...



Guilford Gliadel Glioma Trial Shows Consistent Modest Benefit – Cmte.

Guilford's Gliadel Wafer demonstrates a consistent, if modest, benefit in treatment of newly diagnosed malignant glioma, FDA's Oncologic Drugs Advisory Committee concluded

Guilford Gliadel Glioma Trial Shows Consistent Modest Benefit – Cmte.

Guilford's Gliadel Wafer demonstrates a consistent, if modest, benefit in treatment of newly diagnosed malignant glioma, FDA's Oncologic Drugs Advisory Committee concluded

Guilford Gliadel First-Line Use: Data Stratification To Be Considered By Cmte.

Guilford's Gliadel Wafer stratification of clinical results will be considered by FDA's Oncologic Drugs Advisory Committee in its review of the drug for first-line treatment of malignant glioma, originally scheduled for Sept. 11.

Related Content

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel